Tiger Brokers

BUZZ-Amylyx rises on late-stage trial update for low-blood sugar drug

Reuters
Dec 04, 2024
BUZZ-Amylyx rises on late-stage trial update for low-blood sugar drug

** Shares of drug developer Amylyx Pharmaceuticals AMLX.O rise 1.9% to $5.45 premarket

** Co announces late-stage trial design for its experimental GLP-1 antagonist treatment, avexitide, to treat a type of low blood sugar called post-bariatric hypoglycemia $(PBH)$

** PBH is a condition that affects approximately 8% of people who have undergone bariatric surgery- AMLX

** The trial is designed to evaluate FDA-agreed upon primary goal of reduction in hypoglycemia or low blood sugar events- AMLX

** Co expects to dose the first study participant in the first quarter of 2025, followed by expected completion of recruitment in 2025, and anticipates topline data in 2026

** The late-stage trial will test the efficacy and safety of avexitide in participants with PBH following gastric bypass surgery

** Up to last close, stock was down 63.7% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10